Document is current
Any future updates will be listed below
-
Authors
Jouve, Charlène https://orcid.org/0000-0002-5792-4621
Ruiz-Velasco, Andrea https://orcid.org/0000-0003-0660-5855
Donnarumma, Erminia
Le Borgne, Rémi https://orcid.org/0000-0002-5389-9721
Momken, Iman
Pereira, Céline
Seguret, Magali
Vermersch, Eva https://orcid.org/0000-0003-4813-2355
Vimont, Elodie
Nemazanyy, Ivan https://orcid.org/0000-0001-8080-839X
Bertrand, Luc https://orcid.org/0000-0003-0655-7099
Wai, Timothy https://orcid.org/0000-0002-6770-6222
Verbavatz, Jean-Marc https://orcid.org/0000-0002-4654-1174
Mericksay, Mathias https://orcid.org/0000-0002-6779-092X
Hulot, Jean-Sébastien https://orcid.org/0000-0001-5463-6117
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 4 September 2025
First Online: 9 October 2025
Competing interests
: J.S.H. has received speaker, advisory board or consultancy fees from Alnylam, Amgen, Astra Zeneca, Bayer, Boerhinger Ingelheim, Novartis, Novo Nordisk, all unrelated to the present work. Other authors declare no competing interests.
